Dupixent® (dupilumab) late-breaking data from notus confirmatory phase 3 copd trial presented at ats and published in the new england journal of medicine

Notus results confirm landmark data from the phase 3 boreas trial and show dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (copd) with evidence of type 2 inflammation
REGN Ratings Summary
REGN Quant Ranking